A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a single arm, open label study of up to 24 prostate cancer patients scheduled for
prostatectomy and/or pelvic lymph node dissection. Patients receive a single IV dose of
99mTc-MIP-1404 (study drug) followed by SPECT/CT scan 3-6 hours after injection. As standard
of care, patients will undergo prostatectomy and/or pelvic lymph node dissection (PLND)
within two weeks of study drug dosing. 99mTc-MIP-1404 image data will be evaluated for
visible uptake and compared with histopathology.